Back to Directory

Sargramostim

Performance & Endurance

GM-CSF for stimulating white blood cell production after chemotherapy or transplant.

Key Benefits

  • ✓Increases white blood cells
  • ✓Post-chemotherapy recovery
  • ✓Bone marrow transplant support
  • ✓Reduces infection risk
  • ✓Accelerates engraftment

Dosing Information

Dosage Range
250 mcg/m²
Frequency
Daily
Typical Duration
2-4 weeks typically

Detailed Protocol

Administered via subcutaneous injection or IV infusion daily during recovery period after chemotherapy or transplant. Hospital or close medical supervision. Prescription only.

About Sargramostim

Sargramostim (Leukine) is recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Stimulates production of neutrophils, monocytes, and macrophages. FDA-approved for multiple indications related to bone marrow recovery.

Research Notes

FDA-approved for myeloid reconstitution after chemotherapy, transplant, and acute radiation syndrome. Widely used in oncology. Yeast-derived recombinant protein.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Bone pain
  • •Fever
  • •Injection site reactions
  • •Myalgia
  • •Headache
  • •Rash

Always consult with a healthcare professional before starting any peptide therapy.